(Q33546421)

27 July 2017

title

Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status (English)

1 reference

27 July 2017

Marc R Toglia

1

1 reference

27 July 2017

Donald R Ostergard

2

1 reference

27 July 2017

Rodney A Appell

3

1 reference

27 July 2017

Masakazu Andoh

4

1 reference

27 July 2017

Allam Fakhoury

5

1 reference

27 July 2017

Iqbal F Hussain

6

1 reference

27 July 2017

publication date

26 March 2010

1 reference

International Urogynecology Journal and Pelvic Floor Dysfunction

27 July 2017

published in

1 reference

27 July 2017

volume

21

1 reference

27 July 2017

issue

7

1 reference

27 July 2017

page(s)

847-854

1 reference

Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis

27 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00192-010-1120-6

Reviewing the ICS 2002 terminology report: The ongoing debate

21 January 2018

1 reference

12 December 2020

Prevalence and burden of overactive bladder in the United States

1 reference

12 December 2020

The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects

1 reference

12 December 2020

Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

1 reference

12 December 2020

The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

1 reference

12 December 2020

Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q

1 reference

12 December 2020

Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin

1 reference

12 December 2020

Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder

1 reference

12 December 2020

Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

1 reference

12 December 2020

Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder

1 reference

12 December 2020

Validation of the urgency perception scale

1 reference

12 December 2020

Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia

1 reference

12 December 2020

The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis

1 reference

12 December 2020

A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials

1 reference

12 December 2020

Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms

1 reference

12 December 2020

Increased warning time with darifenacin: a new concept in the management of urinary urgency

1 reference

12 December 2020

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

1 reference

12 December 2020

The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder

1 reference

12 December 2020

Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial

1 reference

12 December 2020

Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder

1 reference

12 December 2020

10.1007/S00192-010-1120-6

Identifiers

DOI

1 reference

Dimensions Publication ID

27 July 2017

1042134684

0 references

1 reference